Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Enobosarm

QUALITY

Veru Inc · Phase 2 · Completed · Enrollment 168

NCT06282458

ArmPopulationDoseWeeksEstimandWeight change
Semaglutide and Enobosarm 3 mg QD by mouth (E3G) dailyObesity or overweight3 mg1n/rn/r
Semaglutide and Enobosarm 6 mg QD by mouth (E6G) dailyObesity or overweight6 mg1n/rn/r
GLP-1 receptor agonist and Placebo QD by mouth (PG) dailyObesity or overweightn/r1n/rn/r